CDKN2A and familial pancreatic carcinoma: Several studies have demonstrated that numerous genes with deregulated methylation status, such as KRAS, CDKN2A, TP53, CD1D, MUC4, and MUC1 play vital roles in the progression of pancreatic cancer (6–8).